Literature DB >> 11555379

Diagnostic utility of CYFRA 21-1 in malignant pleural effusion.

W Dejsomritrutai1, S Senawong, B Promkiamon.   

Abstract

OBJECTIVE: The diagnostic utility of the tumour marker CYFRA 21-1 in malignant pleural effusion is not yet clear. This study was designed to evaluate the diagnostic utility of serum and pleural fluid CYFRA 21-1 in malignant pleural effusion.
METHODOLOGY: The validity of serum and pleural fluid CYFRA 21-1 was determined in 62 patients with exudative pleural effusion (27 malignant and 35 benign). The diagnosis of malignant pleural effusion was defined by cytological or histological results.
RESULTS: A statistically significant difference between the geometric means of CYFRA 21-1 levels in pleural fluid of benign and malignant aetiologies was observed (11.2 vs 63.3 ng/mL, P < 0.0001). In addition, there was a significant difference in the serum levels (0.95 vs 5.55 ng/mL, P < 0.0001). The sensitivity and specificity of pleural fluid CYFRA 21-1 in malignant pleural effusion, at the cut-off value of 55 ng/mL, was 74.1% and 97.1%, respectively. The sensitivity and specificity of serum CYFRA 21-1, at the cut-off value of 2.5 ng/mL, was 81.5% and 97.1%, respectively. Using a combination of serum and pleural fluid CYFRA 21-1 level, the sensitivity increased to 88.9%.
CONCLUSION: Serum and pleural fluid CYFRA 21-1 are useful as measures in differentiating malignant from benign pleural effusion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555379     DOI: 10.1046/j.1440-1843.2001.00332.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

1.  Evaluation of serum cyfra21 in patients with pleural effusion.

Authors:  Q Azimi; B Rezadoost; M Jalali Nadoushan; A Davati
Journal:  Iran Red Crescent Med J       Date:  2012-10-30       Impact factor: 0.611

Review 2.  Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.

Authors:  Ping Gu; Gang Huang; Yumei Chen; Cuiying Zhu; Jimin Yuan; Shile Sheng
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 3.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  Differential diagnostic CYFRA 21-1 level for benign and malignant pleural effusions: a meta-analysis in the Chinese population.

Authors:  Rong Biaoxue; Yang Shuanying; Cai Xiguang; Zhang Wei; Li Wei
Journal:  Arch Med Sci       Date:  2012-10-08       Impact factor: 3.318

5.  Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.

Authors:  P Korczynski; R Krenke; A Safianowska; K Gorska; M B Abou Chaz; M Maskey-Warzechowska; A Kondracka; J Nasilowski; R Chazan
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

6.  Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer.

Authors:  Sushil Kumar Sharma; Sanjay Bhat; Vikas Chandel; Mayank Sharma; Pulkit Sharma; Sakul Gupta; Sashank Sharma; Aijaz Ahmed Bhat
Journal:  J Carcinog       Date:  2015-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.